Noradrenaline Aguettant (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Noradrenaline Aguettant, is a sympathomimetic amine presented as an injectable solution for intravenous use. It acts rapidly to increase vascular tone and cardiac output, making it essential in the management of severe hypotension, septic shock, and cardiac arrest.

GNH USA supplies Noradrenaline Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides reliable logistics for critical care medicines across global markets.

Noradrenaline Aguettant is employed as a potent vasopressor to treat acute, life‑threatening states of low systemic vascular resistance and blood pressure. - Hypotension: restores arterial pressure to maintain organ perfusion. - Septic shock: counteracts vasodilatory failure to improve hemodynamics. - Cardiac arrest: supports coronary and cerebral perfusion during resuscitation. - Vasodilatory shock: provides vasoconstriction to stabilize systemic blood pressure.

Noradrenaline Aguettant may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Tachycardia: increased heart rate. - Nausea: gastrointestinal discomfort. - Peripheral vasoconstriction causing cold extremities: reduced skin temperature.

Serious or Rare Side Effects: - Severe hypertension: dangerously high blood pressure. - Cardiac ischemia: reduced coronary blood flow. - Tissue necrosis at infusion site: severe local damage if extravasation occurs. - Pulmonary edema: fluid accumulation in lungs leading to respiratory compromise.

When using Noradrenaline Aguettant, careful clinical monitoring and adherence to safety measures are essential. - Dose titration: adjust infusion rate to target blood pressure. - Cardiac monitoring: continuously observe heart rhythm and rate. - Peripheral perfusion: assess limb circulation during infusion. - Contraindications: avoid in patients with uncontrolled hypertension. - Drug interactions: review concomitant vasodilators and MAO inhibitors. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline Aguettant can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Tricyclic antidepressants: additive vasoconstriction. - Direct‑acting vasodilators (e.g., nitroprusside): antagonistic effect.

Moderate Interactions (Monitor Closely): - β‑blockers: may blunt β1‑mediated cardiac effects. - Calcium channel blockers: potential additive cardiovascular effects. - Diuretics: may exacerbate volume depletion and hypotension.